Correlation Between Tscan Therapeutics and Repligen

Can any of the company-specific risk be diversified away by investing in both Tscan Therapeutics and Repligen at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tscan Therapeutics and Repligen into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Tscan Therapeutics and Repligen, you can compare the effects of market volatilities on Tscan Therapeutics and Repligen and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tscan Therapeutics with a short position of Repligen. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tscan Therapeutics and Repligen.

Diversification Opportunities for Tscan Therapeutics and Repligen

0.02

Correlation Coefficient

Tscan Therapeutics  Repligen

Significant diversification

The 3 months correlation between Tscan and Repligen is 0.02. Overlapping area represents the amount of risk that can be diversified away by holding Tscan Therapeutics and Repligen in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Repligen and Tscan Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tscan Therapeutics are associated (or correlated) with Repligen. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Repligen has no effect on the direction of Tscan Therapeutics i.e., Tscan Therapeutics and Repligen go up and down completely randomly.

Pair Corralation between Tscan Therapeutics and Repligen

Given the investment horizon of 90 days Tscan Therapeutics is expected to under-perform the Repligen. In addition to that, Tscan Therapeutics is 1.61 times more volatile than Repligen. It trades about -0.12 of its total potential returns per unit of risk. Repligen is currently generating about 0.05 per unit of volatility. If you would invest  14,193  in Repligen on September 12, 2024 and sell it today you would earn a total of  1,001  from holding Repligen or generate 7.05% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	98.44%
Values	Daily Returns

Tscan Therapeutics  vs.  Repligen

Tscan Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Tscan Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Repligen

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Repligen are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very fragile technical and fundamental indicators, Repligen may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Tscan Therapeutics and Repligen

The main advantage of trading using opposite Tscan Therapeutics and Repligen positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tscan Therapeutics position performs unexpectedly, Repligen can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Repligen will offset losses from the drop in Repligen's long position.

The idea behind Tscan Therapeutics and Repligen pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.